Alx Oncology Holdings (ALXO) Liabilities and Shareholders Equity (2019 - 2026)

Alx Oncology Holdings has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $178.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 47.5% year-over-year to $178.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $415.4 million (down 37.91% YoY) and the FY2025 annual result came in at $59.0 million, down 60.04% from the prior year.
• Liabilities and Shareholders Equity rose to $178.3 million in Q1 2026 per ALXO's latest filing, from $59.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $363.7 million in Q1 2022 and troughed at $59.0 million in Q4 2025.
• A 5-year average of $212.8 million and a median of $214.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity tumbled 60.04% in 2025, then jumped 47.5% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $306.5 million in 2022, then slipped by 20.86% to $242.6 million in 2023, then plunged by 39.08% to $147.8 million in 2024, then sank by 60.04% to $59.0 million in 2025, then jumped by 202.02% to $178.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $178.3 million, $59.0 million, and $82.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.